Registration Dossier
Registration Dossier
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 700-993-7 | CAS number: -
Endpoint summary
Administrative data
Link to relevant study record(s)
Description of key information
Key value for chemical safety assessment
Additional information
The following remarks on toxicokinetics are based on the physico-chemical properties of the substance and on toxicological data. Experimental studies on toxicokinetics were not performed.
The substance is a colourless liquid (Neuland, 2012) with a vapour pressure under normal ambient conditions of 0.21 Pa (2.1 x 10-3 mbar) at 20 °C (Fonseca, 2012). From these data vapour inhalation might be a route of exposure whereas the vapour pressure is characterized by DEG which is contained in the multi constituent substance up to 57 %. However systemic availability of Ester PSA + DEG after inhalative exposure is not proven due to the NOAEL (= 1000 mg/kg = limit dose) in the subacute oral study (Popp, 2013) whereas local irritating effect is expected for Ester PSA + DEG from the pH value of 2 and the positive responses in the in vitro test systems for ocular irritation/damage if the intire multi constituent substance reaches the lung.
Although the physico-chemical characteristics of the substance (soluble in demineralized water in each ratio to clear homogenous solutions(10000 mg/L) at 20°C, Neuland, 2012), log Pow of 1 at 25 °C (Garcia-Sanchez, 2013)) and a molecular mass of 248 g/mol (Prüm, 2012) suggest intestinal absorption after oral intake the data on acute oral toxicity in rats (LD50 cut off> 5000 mg/kg bw, Gillissen, 2012) and the results of a subacute oral study in rats (Popp, 2013) with a NOAEL of 1000 mg/kg bw for rats provide no evidence for that assumption.
Due to the high water solubility and a molecular mass of 248 g/mol dermal uptake of Ester PSA + DEG is likely to be low, even if a log Pow of 1 at 25°C favour dermal absorption particularly if water solubility is high. The study results on acute dermal toxicity (rat, LD50 > 2000 mg/kg bw; Gillissen, 2012) skin irritation (no systemic effects, Leuschner, 2012) and skin sensitization (LLNA, negative; Vohr 2012) confirmed both assumptions because lack of systemic toxicity may reflect that there is no dermal uptake or Ester PSA + DEG has no effect.
Deducing from the repeated dose toxicity study, where no systemic toxicity was reported, no potential for accumulation is to be expected for the substance.
Based on the results of in vitro genotoxicity tests (negative with and without metabolic activation in Ames test, Nern, 2012; HPRT test, Wollny, 2012; Micronucleus test, Nern, 2012) it is concluded that DNA-reactive metabolites of ester PSA + DEG will most probably not be generated in mammals in the course of hepatic biotransformation if bioavailability is given.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
